Program

Break

Forum

Other Event

Plenary Lecture

Pre-Conference Symposium

Product Theater

Sponsored Symposium

Symposium

Tuesday, 01 April, 2025

Time	Hall A	Hall E	Hall B	Hall C	Hall F1	Hall F2	Exhibition	On-Demand Oral Gallery
07:00-08:00								ON-DEMAND SYMPOSIA - ONLINE ONLY
08:00-15:30					PRE-CONFERENCE SYMPOSIUM 01	PRE-CONFERENCE SYMPOSIUM 01
08:45-10:45			AD MECHANISMS AND MOLECULAR SYSTEMS
09:45-10:45	INDUSTRY SYMPOSIUM 01 (NO CME/CPD CREDIT)
10:45-12:45	WHITE MATTER ALTERATIONS AND MRI	ALPHA-SYNUCLEINOPATHIES: DISEASE MECHANISMS, PATHOPHYSIOLOGY	AD & PD: INSIGHTS FROM GENETICS 01
11:00-15:30				PRE-CONFERENCE SYMPOSIUM 02
12:45-13:15							BREAK
13:15-15:30	BIOMARKERS, IMAGING. AND TRANSLATIONAL ASPECTS	ADVANCES IN PD TREATMENT	SYMPTOM DETECTION AND TREATMENT PROGRAMS: HEALTH CORRELATES AND APPS
15:45-16:35	OPENING CEREMONY AND AWARDS
16:35-17:05	PLENARY LECTURE 01
17:05-17:35	PLENARY LECTURE 02
17:35-17:45							SHORT BREAK
17:45-18:45	FORUM 01: VARYING REGULATORY PHILOSOPHIES AND AD APPROVAL PRIORITIES - USA, EU, ASIA, AND OTHER PARTS OF THE WORLD
18:45-19:30	FIRESIDE CHAT 03
19:35-21:25							WELCOME RECEPTION IN EXHIBITION

Wednesday, 02 April, 2025

Time	Hall A	Hall E	Hall B	Hall C	Hall F1	Hall F2	Exhibition/Product Theater	Exhibition	On-Demand Oral Gallery
07:00-08:00									ON-DEMAND SYMPOSIA - ONLINE ONLY
08:00-08:30	PLENARY LECTURE 03: Don Price Memorial Lecture
08:30-08:40								BREAK
08:40-10:40	INDUSTRY SYMPOSIUM 02 (NO CME/CPD CREDIT)	DEMENTIA PREVENTION AND TREATMENT STRATEGIES; DIAGNOSIS AND STAGING OF AD	APOE MECHANISMS AND TREATMENT STRATEGIES	ABETA TOXICITY: OLIGOMERS, PLAQUES AND INTERACTION WITH TAU	EXTRACELLULAR VESICLES AND BRAIN PATHOLOGY	GENETIC AND EPIDEMIOLOGICAL INSIGHTS IN AD & PD
10:40-11:10							PRODUCT THEATER 01 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)	EXHIBITION, POSTERS AND COFFEE BREAK
11:10-12:50	INDUSTRY SYMPOSIUM 03 (NO CME/CPD CREDIT)
12:50-13:50								EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
13:00-13:30							PRODUCT THEATER 02 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
13:50-14:50	FORUM 02: INTEGRATING BLOOD-BASED, CSF AND IMAGING BIOMARKERS WITH DIGITAL TOOLS AND AI IN MCI & AD: HOW CLOSE ARE WE TO VALIDATION IN STANDARD OR PRECISION MEDICINE?
13:50-15:50		TREM2, MICROGLIA: FROM MECHANISMS TO POTENTIAL TREATMENTS	GENETICS OF NEURODEGENERATION: NEW FINDINGS AND ASSOCIATIONS	ALPHA--SYNUCLEIN, AGGREGATION, MISFOLDING, PATHOGENESIS AND TRANSLATIONAL ASPECTS	TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 01	WHITE MATTER ALTERATIONS
14:50-15:50	FORUM 03: IMPROVING THE THERAPEUTIC POTENTIAL OF IMMUNOTHERAPIES IN AD – CAN NOVEL STRATEGIES OR NEXT GENERATION DRUGS HALT OR FURTHER DELAY DISEASE PROGRESSION?
15:50-16:20								EXHIBITION, POSTERS AND COFFEE BREAK
16:20-18:20	INDUSTRY SYMPOSIUM 04 (NO CME/CPD CREDIT)
16:20-18:50		TAU MECHANISMS 01	ANCESTRY AND GENETICS OF NEURODEGENERATION	PD & LBD: ADVANCES IN DIAGNOSIS	TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 02	MITOCHONDRIA AND NEURODEGENERATION, GLUCOCORTICOID VULNERABILITY
18:25-19:25	NEURODEGENERATIVE DISEASES: DIAGNOSIS & STAGING

Thursday, 03 April, 2025

Time	Hall A	Hall E	Hall B	Hall C	Hall F1	Hall F2	Exhibition	On-Demand Oral Gallery
07:00-08:00								ON-DEMAND SYMPOSIA - ONLINE ONLY
08:00-08:30	PLENARY LECTURE 04: The Eric N. Birch Memorial Lecture
08:40-10:40	INDUSTRY SYMPOSIUM 05 (NO CME/CPD CREDIT)	CHOLINERGIC MECHANISMS IN AD AND PD (1)	APOE: DISEASE MECHANISMS AND BIOLOGY	AUTOPHAGY	DISEASE AND RESILIENCE MECHANISMS: INFLAMMATION, ASTROGLIA, AND MORE	SEX SIMILARITIES AND DIFFERENCES IN BIOMARKERS & PATHOPHYSIOLOGY
10:40-11:10							EXHIBITION, POSTERS AND COFFEE BREAK
11:10-12:50	INDUSTRY SYMPOSIUM 06 (NO CME/CPD CREDIT)
12:50-13:50							EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
13:50-15:50	INDUSTRY SYMPOSIUM 07 (NO CME/CPD CREDIT)	ABETA TARGETING THERAPIES IN AD 01	LIPIDS IN AD & PD	MECHANISMS (TDP-43, C9ORF72, TMEM106B) AND CLINICAL TRIALS IN FTD, ALS AND NEURODEGENERATION 01	FLUID BIOMARKERS AND MULTIMODAL IMAGING FOR DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION	Α-SYNUCLEIN AGGREGATION. PROPAGATION AND NEUROTOXICITY
15:50-16:20							EXHIBITION, POSTERS AND COFFEE BREAK
16:20-17:20	INDUSTRY SYMPOSIUM 08 (NO CME/CPD CREDIT)
16:20-18:20		ARIA, MICROBLEEDS, CAA	TAU MECHANISMS 02 & PSP	PET AND MULTIMODAL IMAGING	FLUID BIOMARKERS. AND IMAGING 01	CELL, MOLECULAR AND SYSTEMS BIOLOGY: METABOLOMICS, TRANSCRIPTOMICS, LIPIDOMICS, PROTEOMICS
17:30-18:30	FORUM 04: TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION – WHAT COULD BE PROMISING STRATEGIES? SMALL MOLECULES FOR SYMPTOMATIC & DISEASE MODIFICATION?
18:30-18:40							SHORT BREAK
18:40-20:15	INDUSTRY SYMPOSIUM 09 (NO CME/CPD CREDIT)

Friday, 04 April, 2025

Time	Hall A	Hall E	Hall B	Hall C	Hall F1	Hall F2	Exhibition	On-Demand Oral Gallery
07:00-08:00								ON-DEMAND SYMPOSIA - ONLINE ONLY
08:00-08:30	PLENARY LECTURE 05
08:30-08:40							BREAK
08:40-10:40	INDUSTRY SYMPOSIUM 10 (NO CME/CPD CREDIT)	CEREBROVASCULAR CHANGES, CAA, BBB 01	PREVENTION AND THERAPEUTIC INTERVENTIONS IN AD	PATHOLOGY OF NEURODEGENERATIVE DISEASES: UPDATES AND NEW FINDINGS	BRAIN GUT INTERACTIONS, MICROBIOME	FLUID BIOMARKERS AND IMAGING 02
10:40-11:10							EXHIBITION, POSTERS AND COFFEE BREAK
11:10-12:50	INDUSTRY SYMPOSIUM 11 (NO CME/CPD CREDIT)
12:50-13:50							EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
13:50-15:50	INDUSTRY SYMPOSIUM 12 (NO CME/CPD CREDIT)	FLUID AND DIGITAL BIOMARKERS AND IMAGING	IMMUNITY AND INFLAMMATION IN NEURODEGENERATION	LRKK2, ALPHA-SYNUCLEIN, PARKIN: DIAGNOSIS AND THERAPEUTIC TARGETS	TAU AGGREGATION, PROPAGATION, DEPOSITION, AND PROTEIN MODIFICATIONS	RESILIENCE, LONGEVITY AND DRIVERS OF DISEASE PROGRESSION
15:50-16:20							EXHIBITION, POSTERS AND COFFEE BREAK
16:20-17:20	INDUSTRY SYMPOSIUM 13 (NO CME/CPD CREDIT)
16:20-18:20		MRI	FLUID BIOMARKERS AND IMAGING 03	DISEASE MECHANISMS, SYNAPSE PATHOLOGY & FUNCTION; INFLAMMATION: THERAPEUTIC TARGETS	MICROGLIA	AD & PD: INSIGHTS FROM GENETICS 02
17:25-18:30	FORUM 05: NOVEL APPROACHES TO ACCELERATE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES LINKED TO PD, LBD AND MSA
18:30-18:40							SHORT BREAK
18:40-20:00	INDUSTRY SYMPOSIUM 14 (NO CME/CPD CREDIT)
18:40-19:40			PATHOPHYSIOLOGY, NEUROGENESIS. GLYMPHATIC/LYMPHATIC INFLAMMATION	CELL REPLACEMENT THERAPY & DIAGNOSTICS: CELLS, GLIA AND GRAFTS	TAU PATHOLOGIES, PSP, LBD	COGNITIVE TRAJECTORIES, DIGITAL TWINS, POSTERIOR CORTICAL ATROPHY

Saturday, 05 April, 2025

Time	Hall A	Hall E	Hall B	Hall C	Hall F1	Hall F2	Exhibition	On-Demand Oral Gallery
07:00-08:00								ON-DEMAND SYMPOSIA - ONLINE ONLY
08:00-08:30	PLENARY LECTURE 06
08:30-08:40							BREAK
08:40-10:40	ABETA TARGETING THERAPIES IN AD 02	BIOMARKERS IN CLINICAL USE ACROSS DEMENTIAS	TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS	CEREBROVASCULAR CHANGES, CAA, BBB 02	FLUID BIOMARKERS AND IMAGING IN AD, PD , LBD. PSP AND SMALL- VESSEL DISEASE	MECHANISMS (TDP-43, C9ORF72, TMEM106B) AND CLINICAL TRIALS IN FTD, ALS AND NEURODEGENERATION 02
10:40-11:10							EXHIBITION, POSTERS AND COFFEE BREAK
11:10-13:10	TAUOPATHIES: CHALLENGES IN TARGETING TAU	ABETA & TAU IMMUNOTHERAPIES	NOVEL THERAPEUTIC STRATEGY BEYOND AMYLOID AND TAU: NEUROTRANSMITTERS AND RECEPTORS: GLP-1 ANALOGUES	CHOLINERGIC MECHANISMS IN AD AND PD (2)	AD & PD: TOWARDS NOVEL THERAPEUTIC INTERVENTION	FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD 01
13:10-14:10							EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
14:10-15:10	FORUM 06: CHALLENGES AND OPPORTUNITIES FOR ANTI-TAU THERAPIES IN CLINICAL TRIALS – HOW CAN WE MAKE HOPES COME TRUE?
14:10-16:10		PD AND LBD: ADVANCES IN DIAGNOSIS AND DRUG DEVELOPMENT	SECRETASES AND APP PROCESSING	ALPHA-SYNUCLEINOPATHIES: MECHANISMS, PATHOPHYSIOLOGY AND MODELLING OF PROGRESSION 02	EEG, DIAGNOSTCS AND OTHER ASSESSMENT TOOLS	FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD 02
15:10-16:10	FORUM 07: THERAPY FOR AD, PD & LBD: NOVEL TRANSLATIONAL MODELS, NEW RECEPTOR- AND NEUROINFLAMMATION-BASED TARGETS – HOW CLOSE ARE WE TO SUCCESS?
16:10-16:40							EXHIBITION, POSTERS AND COFFEE BREAK
16:40-17:40	FORUM 08: DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TO APPROVAL – HOW TO DEFINE SUCCESS?
16:40-18:40		ADVANCES IN AD DRUG DEVELOPMENT 02	ADVANCES IN PD, LBD AND MSA DRUG DEVELOPMENT	TRANSLATIONAL DRUG DEVELOPMENT AND EXPERIMENTAL MODELS	COVID-19 AND IMPACTS ON NEURODEGENERATION	FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD 03
17:45-19:00	ADVANCES IN AD DRUG DEVELOPMENT 03
19:00-19:20	CLOSING CEREMONY